1. Home
  2. IFRX vs VTSI Comparison

IFRX vs VTSI Comparison

Compare IFRX & VTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • VTSI
  • Stock Information
  • Founded
  • IFRX 2007
  • VTSI 1993
  • Country
  • IFRX Germany
  • VTSI United States
  • Employees
  • IFRX N/A
  • VTSI N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • VTSI Miscellaneous manufacturing industries
  • Sector
  • IFRX Health Care
  • VTSI Consumer Discretionary
  • Exchange
  • IFRX Nasdaq
  • VTSI Nasdaq
  • Market Cap
  • IFRX 53.5M
  • VTSI 60.6M
  • IPO Year
  • IFRX 2017
  • VTSI N/A
  • Fundamental
  • Price
  • IFRX $1.60
  • VTSI $5.99
  • Analyst Decision
  • IFRX Strong Buy
  • VTSI Strong Buy
  • Analyst Count
  • IFRX 4
  • VTSI 1
  • Target Price
  • IFRX $7.75
  • VTSI $7.00
  • AVG Volume (30 Days)
  • IFRX 577.2K
  • VTSI 85.8K
  • Earning Date
  • IFRX 08-07-2025
  • VTSI 08-11-2025
  • Dividend Yield
  • IFRX N/A
  • VTSI N/A
  • EPS Growth
  • IFRX N/A
  • VTSI N/A
  • EPS
  • IFRX N/A
  • VTSI 0.10
  • Revenue
  • IFRX $191,224.00
  • VTSI $27,068,543.00
  • Revenue This Year
  • IFRX N/A
  • VTSI $10.31
  • Revenue Next Year
  • IFRX $1,336.36
  • VTSI $12.71
  • P/E Ratio
  • IFRX N/A
  • VTSI $59.85
  • Revenue Growth
  • IFRX 54.36
  • VTSI N/A
  • 52 Week Low
  • IFRX $0.71
  • VTSI $3.57
  • 52 Week High
  • IFRX $2.82
  • VTSI $8.53
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 89.35
  • VTSI 47.45
  • Support Level
  • IFRX $0.82
  • VTSI $5.34
  • Resistance Level
  • IFRX $0.96
  • VTSI $6.10
  • Average True Range (ATR)
  • IFRX 0.11
  • VTSI 0.32
  • MACD
  • IFRX 0.06
  • VTSI 0.01
  • Stochastic Oscillator
  • IFRX 100.00
  • VTSI 37.26

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.

Share on Social Networks: